Inflammatory bowel disease is very different from gastroenteritis! Frequent diarrhea will also increase the risk of bowel cancer Life | QUANTITY

Inflammatory bowel disease, nongastroenteritis, recurrent diarrhea also increases the risk of bowel cancer

Want to run to the toilet at every turn, frequent diarrhea, and even sit on the toilet before sitting in a chair when entering the office or school.

Lin Jingbin, director of the Center for Prevention and Control of Liver Disease at the Affiliated Hospital of Sun Yat-Sen Medical University, said that the symptoms of these two diseases are similar, but if there is no differential diagnosis and treatment, the consequences will be very great. Different, especially inflammatory bowel disease can cause rectal abscess, rectal fistula, and intestinal strictures. Surgical treatment is required, and it can also greatly increase the chance of developing bowel cancer.

Inflammation of the bowel causes joint, skin and joint problems, which increases the risk of bowel cancer

Inflammatory bowel disease (Inflammatory bowel disease, IBD) is divided into ulcerative colitis and Crohn’s disease, which is an immune disorder. Director Lin Jingbin said that in Taiwan, the incidence rate of ulcerative colitis is higher than that of Crohn’s disease, and it occurs more often in young people in their 20s, and the probability of men is higher than women in the trend of.

The cause of inflammatory bowel disease is unknown, and may be related to genetic defects and inappropriate drug use. Director Lin Jingbin believes it is also related to the imbalance of intestinal bacteria caused by a western diet. If it is not diagnosed and treated in time, it will also cause systemic reactions. In addition to intestinal symptoms such as rectal fistula, rectal abscess, and intestinal stenosis, complications can also occur in the skin, joints and eyes.

In particular, chronic intestinal inflammation can easily lead to mucosal degeneration and increase the risk of colon and rectal cancer. In particular, the longer the disease time, the more intestinal invasion, and the more complications, the higher the risk of colorectal cancer.

Although both are related to inflammatory bowel disease, Crohn’s disease is still different from ulcerative colitis. Director Lin Jingbin further explained that the onset of ulcerative colitis is limited to the rectum and large intestine, while Crohn’s disease is entire intestinal tract (large and small intestine). ) Everyone will break, the likelihood of complications is high, and the chance of requiring intestinal plastic surgery is high.

Biologics provide sustained symptom relief, aid mucosal healing and reduce surgical risk

Patients with moderate to severe inflammatory bowel disease often have to go to the toilet, severely affecting quality of life, work, making friends, and mood will all be affected. Fortunately, there are more and more therapeutic drugs for inflammatory bowel disease, ranging from traditional anti-inflammatory drugs to steroids, immunomodulators, immunosuppressants, etc., as well as newer biological agents, and health insurance covers the part most of them, which can help patients If the treatment reaches the target, that is, there is a continuous relief of symptoms, imaging and pathological examinations show that the mucosa has improved, the chances of having surgery, going to the hospitalization and recurrence are reduced, there is an opportunity to reduce or stop steroids, and patients can have a normal life.

Among them, for patients with more severe ulcerative colitis and a poor prognosis, the international treatment guidelines recommend adopting an inverted pyramid approach, starting with biological agents. Currently, there are many types of biologic agents available clinically, including different injection frequencies such as semi-monthly, monthly and quarterly injections; different injection methods such as subcutaneous injection and intravenous injection; and different mechanisms for different inflammatory cytokines. The doctor will adjust the medicine according to the condition of the disease, lifestyle, occupation and healing effect.

However, due to limited health insurance resources, Director Lin Jingbin admitted that, at present, patients with moderate to severe inflammatory bowel disease do not respond well to traditional medicines, leading to recurrent attacks, or when no they can tolerate traditional medicines, they can use biological agents.

The relapse rate is high during health insurance withdrawals, and doctors are calling for an extension of the payment time of biological agents

National health insurance pays for biologic agents for patients with moderate to severe inflammatory bowel disease, which is a great virtue. Director Lin Jingbin pointed out that the use of biological agents for inflammatory bowel disease is only paid for one year, When the time is up, the drugs must be stopped regardless of the severity of the symptoms. Instead, many patients relapse during this period of drug withdrawal, and even have to increase the use of steroids, which affects the long-term condition of the disease. The stability and control of the disease is call on the government to give more care and support to the patients.

If people have abnormal defecation conditions such as regular diarrhea, constipation while wanting to defecate, Director Lin Jingbin suggests that they should seek medical examination, as long as calprotectin examination and capsule endoscopy imaging examination of the tract can be used whole intestine to find out and it is inflammation Sexual intestinal diseases. After being diagnosed with inflammatory bowel disease, there is no need to be afraid. With the development of medicine, there are currently many drugs that can help reduce inflammation, stabilize disease control, and achieve the goal of intestinal mucosa.